Tag

Major Depressive Disorder

All articles tagged with #major depressive disorder

health4 days ago•7 min saved

Creatine May Enhance Depression Treatments, Early Evidence Shows

A systematic review of five randomized trials suggests creatine monohydrate may help depressive symptoms when added to existing depression treatments, with some studies showing improvement when paired with the antidepressant escitalopram or with cognitive behavioral therapy, but others showing no benefit in teen girls or in bipolar depression; findings are preliminary and creatine should supplement—not replace—standard care, with larger trials needed to identify who may benefit and the optimal use.

via Fox News|

#brain-energy-metabolism #creatine #depression

science2 months ago•4 min saved

Global review finds strong cannabis-use disorder link with major depression, but causality remains unclear

A global review of 55 studies involving over 3.2 million people finds a strong association between cannabis use disorder (CUD) and major depressive disorder (MDD). About 32% of people with CUD also have MDD, and over 10% of people with MDD have CUD, rates higher than in the general population. The authors caution that causality cannot be established and suggest shared risk factors or self-medication may contribute; they call for routine screening in treatment settings and note that while pharmacological options are unclear, psychological therapies show promise. The work was published in The Journal of Psychiatric Research.

via ScienceAlert|

#cannabis-use-disorder #comorbidity #major-depressive-disorder

health8 months ago•14 min saved

FDA Approves Caplyta for Major Depressive Disorder, Offering New Hope

Johnson & Johnson's FDA approval of CAPLYTA (lumateperone) as an adjunctive treatment for major depressive disorder in adults offers a new hope for remission, demonstrating efficacy and a favorable safety profile based on Phase 3 trials, potentially transforming treatment expectations for depression.

via Johnson & Johnson|

#caplyta #fda-approval #health

business10 months ago•4 min saved

AbbVie Acquires Gilgamesh's Psychedelic Depression Therapy in $1.2B Deal

AbbVie is acquiring Gilgamesh Pharmaceuticals' investigational drug bretisilocin, a promising psychedelic therapy in Phase 2 trials for major depressive disorder, aiming to expand its psychiatric treatment portfolio. The drug has shown significant antidepressant effects with a shorter psychoactive duration, and the deal includes up to $1.2 billion in potential payments. This move underscores AbbVie's commitment to innovative mental health treatments.

via AbbVie News Center|

#abbvie #bretisilocin #business

health-and-medicine2 years ago•4 min saved

"How Antidepressants Alleviate Major Depression"

Researchers from the University of Colorado have developed a new framework suggesting that antidepressants treat major depressive disorder (MDD) by restoring brain connectivity and promoting neuroplasticity, rather than correcting a serotonin imbalance. This new understanding aims to improve patient-clinician conversations and reframe public perception of antidepressant efficacy.

via Neuroscience News|

#antidepressants #brain-connectivity #health-and-medicine

health2 years ago•10 min saved

'Navigating Major Depressive Disorder Conversations in the Hispanic Community'

Marisol, a member of the Hispanic community, struggled with Major Depressive Disorder (MDD) due to the stigma surrounding mental health in her culture. After a health scare, she sought help and found a psychiatrist who recommended Trintellix, a medication for MDD. She emphasizes the importance of open dialogue about mental health in the Hispanic community and encourages others to seek help without fear of judgment. Dr. Virmarie Diaz Fernandez, a psychiatrist, stresses the significance of creating a safe space for patients to discuss their mental health.

via Well+Good|

#health #hispanic-community #major-depressive-disorder

health-mental-health2 years ago•3 min saved

"Sexual Dysfunction Linked to Antidepressant Use in 19% of Patients"

A study published in the Journal of Affective Disorders Reports found that 19% of individuals without prior sexual issues reported encountering sexual problems related to the usage of at least one antidepressant. The survey involved 900 people aged 18 to 64 with major depressive disorder, categorizing them based on their antidepressant use over the past year into continuers, switchers, and discontinuers. The study sheds light on the experiences of antidepressant use, highlighting the impact of treatment-emergent sexual dysfunction and the reasons for continuing therapy, switching to a different antidepressant, and discontinuation.

via PsyPost|

#antidepressants #health-mental-health #major-depressive-disorder

health-and-science2 years ago•3 min saved

"Link Found Between Loneliness and Reduced Gray Matter in Men's Brains"

A study using UK Biobank data found that loneliness is associated with reduced gray matter volume in specific brain regions, particularly in men with major depressive disorder. The research suggests a link between loneliness and structural brain changes, highlighting the potential impact of social engagement on brain health in middle-aged men vulnerable to depression. However, the study's cross-sectional design leaves the long-term relationship between brain structure and loneliness unclear, and further research is needed to determine causality between loneliness, major depressive disorder, and observed brain changes.

via PsyPost|

#brain-health #gray-matter-volume #health-and-science

health-and-science2 years ago•7 min saved

Uncovering the Neuropsychological Impact of Rapid-Acting Antidepressants

New research published in Science Translational Medicine reveals that rapid-acting antidepressants like ketamine, psilocybin, and scopolamine can alter negative mood biases in rodent models, shedding light on the neuropsychological mechanisms behind their effects. The study suggests that these drugs not only dampen negative emotional memories but also enhance positive emotional learning, potentially offering new avenues for understanding and treating Major Depressive Disorder. The findings indicate that these rapid-acting antidepressants have long-lasting effects on mood and memory, hinting at potential therapeutic applications for conditions such as PTSD.

via PsyPost|

#health-and-science #ketamine #major-depressive-disorder

health2 years ago•4 min saved

Exploring the Therapeutic Potential of Psilocybin for Mental Health Conditions

A meta-analysis of 13 randomized controlled trials has highlighted the potential of psilocybin-assisted psychotherapy as a treatment for patients with treatment-resistant depression. The analysis found that patients receiving psilocybin therapy showed significantly more improvement in depressive symptoms compared to those who did not receive the treatment. Response rates and remission rates were higher in the psilocybin group, and the positive effects of psilocybin therapy were observed shortly after administration and could last for several months. While psilocybin was generally well-tolerated, some participants experienced non-serious side effects. However, careful screening and monitoring of participants, especially those with a complex psychiatric history, is necessary. Further research is needed to establish psilocybin-assisted psychotherapy as an accepted medical alternative.

via PsyPost|

#health #major-depressive-disorder #meta-analysis

health2 years ago•0 min saved

FDA Finally Approves Long-Awaited Major Depressive Drug

The FDA has finally approved a tablet developed by Fabre-Kramer Pharmaceuticals for adults with major depressive disorder, after a 24-year-long process involving multiple companies and regulatory scrutiny over its efficacy. The drug, known as Exxua (gepirone), is expected to be available in pharmacies in early 2024.

via Endpoints News|

#efficacy #exxua #fabre-kramer-pharmaceuticals

business2 years ago•1 min saved

Sage Therapeutics Faces Stock Plunge and FDA Approval Setback

Sage Therapeutics' stock plummeted by 49% in premarket trading after the FDA approved its zuranolone treatment for postpartum depression but not for major depressive disorder (MDD). The FDA's approval makes zuranolone the first and only oral treatment for postpartum depression, a condition that affects one in eight new mothers in the US. Sage is currently reviewing the FDA's feedback and considering its next steps, including resource allocation and a workforce reorganization. CEO Barry Greene stated that the company plans to provide more details and next steps before the end of the third quarter. Biogen, which co-developed zuranolone, also saw a decline in its stock.

via MarketWatch|

#business #fda #major-depressive-disorder

mental-health3 years ago•3 min saved

"Is tDCS Losing its Role in Treating Major Depression?"

A triple-blind, randomized, sham-controlled trial found that transcranial direct current stimulation (tDCS) does not provide additional benefit when added to selective serotonin reuptake inhibitor (SSRI) therapy for adults with major depressive disorder (MDD). The study showed no difference in improvement in depression scores between active and sham tDCS. While the results question the efficacy of tDCS as an adjunct treatment for MDD, researchers suggest that combining tDCS with specific behavioral or cognitive interventions or personalizing tDCS based on individual MRI-based computational modeling may hold promise. Further research is needed to explore placebo response and individualized treatment options for MDD.

via Medscape|

#antidepressant-therapy #clinical-trial #efficacy

health3 years ago•3 min saved

Sexual Activity in Early Life Linked to Major Depressive Disorder, Study Finds

A new study published in the Journal of Affective Disorders suggests a causal link between early sexual intercourse and major depressive disorder (MDD). Researchers utilized large-scale genetic data and Mendelian randomization analysis to investigate the relationship between sexual behaviors and MDD. The findings indicate that early sexual intercourse increases the risk of MDD, and delaying the age at first sexual intercourse may have a protective effect against the development of depression. However, the study has limitations, including its focus on the European population and reliance on self-reported data. Nonetheless, the study highlights the importance of addressing depression among sexually active adolescents and the potential benefits of interventions aimed at delaying early sexual activity in preventing or reducing the risk of MDD.

via PsyPost|

#causal-relationship #early-sexual-intercourse #health

health3 years ago•4 min saved

"Groundbreaking Study Identifies Promising Biomarker for Major Depressive Disorder"

Researchers from Korea have identified a neuroimaging-based biomarker, known as the local gyrification index (LGI), for major depressive disorder (MDD). The study found that patients with MDD had significantly lower LGI values in multiple cortical regions compared to healthy individuals, indicating hypogyrification or decreased cortical folding. The findings suggest that abnormal cortical folding patterns may be associated with the dysfunction of neural circuits involved in emotional regulation, contributing to the pathophysiology of MDD. The study's results provide a deeper understanding of MDD and pave the way for future research on genetic factors and targeted medical treatments.

via Medical Xpress|

#biomarker #cortical-folding #health